Loading…
This event has ended. Create your own event on Sched.
Welcome to the Science Summit at UNGA76, a major contribution to advancing Science for the UN SDGs. Online from 14- September - 5 October 2021.
ISC will organise the second edition of the UNGA76 Science Summit around the 76th United Nations General Assembly (SSUNGA76) in September 2021. The objective of the virtual meeting will be to raise awareness of the role and contribution of science to the attainment of the United Nations Sustainable Development Goals. It will demonstrate initiatives that provide models for global science mechanisms and activities in support of the SDGs, particularly in science infrastructure and capacity building. Science is and will enable sustainable economic, environmental, and societal development. Science is more than a funding prioritisation exercise: science is impacting all areas of policy-making and is playing a more critical role in how policy objectives are achieved and the consequent benefit to people everywhere, including responses to global challenges.
Engagement with policy leadership is more important than ever: UNGA76 is a unique forum for science to demonstrate how policy and political leadership can benefit from innovation. Central to this is the role of nonstate actors and the multilateral fora, which increasingly determine how priorities are set. Science needs to be part of this dialogue and inform outputs through thought leadership, evidence, insights, analysis, and innovation.

Registration is available here.
avatar for David Peloquin

David Peloquin

David Peloquin is a partner in the health care group who advises clients on a wide range of legal and regulatory issues in the area of clinical research and related activities. David counsels academic medical centers, life sciences companies, information technology companies and other clients that sponsor, support and conduct research. With a broad client base and knowledge of a range of laws and regulations, from the Common Rule and FDA regulations to HIPAA and GDPR, to state and federal fraud and abuse laws—David offers clients clear, practical advice on how the complex legal landscape intersects with an array of research activities.

In an area that is constantly evolving, David advises clients on the latest guidance across a range of issues. With the onset of COVID-19, he helped clinical laboratories, universities and diagnostic test developers navigate the regulatory implications of testing, assisted companies that were creating diagnostic tests for the very first time, and counselled employers in setting up back-to-work testing programs and, most recently, vaccination programs. In addition to his advisory work, David collaborates with the private equity group to conduct regulatory diligence of clinical research investments and works with the firm’s litigation practice on government and civil investigations involving clinical research.

David’s interest and advocacy in health care are far-reaching, extending to the broader community. He speaks and writes frequently on issues in health care law and data privacy, and has been published in Science magazine and the legal press. As part of his pro bono practice, he advises the Multi-Regional Clinical Trials Center of Harvard and Brigham & Women’s Hospital and leads the team that advises Vivli, a nonprofit organization that collects and shares participant-level anonymized data from clinical trials. David also serves as a Community Member of the Mass General Brigham Institutional Review Board. Before his legal career, David was a project manager for Epic Systems, a leading supplier of electronic medical records.